Presidio Property Trust Inc Preferred Series D

NASDAQ SQFTP

Download Data

Presidio Property Trust Inc Preferred Series D Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -179.77

Presidio Property Trust Inc Preferred Series D Enterprise Value to EBITDA (EV/EBITDA) is -179.77 on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Presidio Property Trust Inc Preferred Series D 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 16.16 on April 01, 2024, which is 108.99% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Presidio Property Trust Inc Preferred Series D 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -183.96 on May 21, 2024, which is -2.33% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Presidio Property Trust Inc Preferred Series D average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -39.30.
NASDAQ: SQFTP

Presidio Property Trust Inc Preferred Series D

CEO -
IPO Date June 11, 2021
Location United States
Headquarters 4995 Murphy Canyon Road, San Diego, CA, United States, 92123
Employees 15
Sector Real Estate
Industry Reit - diversified
Description

Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California. While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19. Presidio owns approximately 6.5% of the outstanding common stock of Conduit Pharmaceuticals Inc., a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development.

Similar companies

ATLCP

Atlanticus Holdings Corp Preferred

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email